SnackNoMore
Well-known member
Well, Novo's CagriSema didn't beat Lilly's Zepbound in the Phase 3 trial. Novo shares took a hit. CagriSema got folks down 23%, while Zepbound hit 25.5%. Looks like Zepbound is still king.
Many are waiting. There are a few in development, but they're monoclonal antibodies and will be very expensive and not easily available. Some peptides are marketed as myostatin inhibitors, but their results and safety are questionable. Enobosarm (Ostarine) has been tested with sema and seems to help people keep muscle while losing fat but is still just phase 1 data. Ostarine has liver and lipid side effects.Light_Life said:Why don't people stack a myostatin inhibitor with a GLP-1 agonist? That way, you could keep or even gain muscle while losing fat.
We use cookies to provide forum features. Optional analytics cookies are only used with your consent. Cookie Policy